Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
154.73 USD | +0.08% |
|
-1.38% | -21.26% |
06-17 | Baird Adjusts Price Target on IQVIA Holdings to $159 From $161, Maintains Neutral Rating | MT |
06-11 | IQVIA Launches New AI Agents for Life Sciences and Healthcare | CI |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 11.36B | 13.87B | 14.41B | 14.98B | 15.4B | |||||
Total Revenues | 11.36B | 13.87B | 14.41B | 14.98B | 15.4B | |||||
Cost of Goods Sold, Total | 7.5B | 9.23B | 9.38B | 9.74B | 10.03B | |||||
Gross Profit | 3.86B | 4.64B | 5.03B | 5.24B | 5.38B | |||||
Selling General & Admin Expenses, Total | 1.76B | 1.93B | 2.04B | 2.04B | 1.98B | |||||
Depreciation & Amortization - (IS) | 1.29B | 1.26B | 1.13B | 1.12B | 1.11B | |||||
Other Operating Expenses | - | - | - | - | - | |||||
Other Operating Expenses, Total | 3.05B | 3.2B | 3.17B | 3.17B | 3.1B | |||||
Operating Income | 810M | 1.45B | 1.86B | 2.07B | 2.28B | |||||
Interest Expense, Total | -416M | -375M | -416M | -672M | -670M | |||||
Interest And Investment Income | 6M | 6M | 13M | 36M | 47M | |||||
Net Interest Expenses | -410M | -369M | -403M | -636M | -623M | |||||
Income (Loss) On Equity Invest. | 7M | 6M | -12M | - | 5M | |||||
Currency Exchange Gains (Loss) | -1M | - | - | - | - | |||||
Other Non Operating Income (Expenses) | -5M | 38M | -54M | 36M | -13M | |||||
EBT, Excl. Unusual Items | 401M | 1.12B | 1.39B | 1.47B | 1.65B | |||||
Restructuring Charges | -52M | -20M | -28M | -84M | -67M | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | 25M | 16M | -27M | 20M | 22M | |||||
Asset Writedown | - | - | - | - | - | |||||
Other Unusual Items | 6M | 17M | 15M | 52M | 71M | |||||
EBT, Incl. Unusual Items | 380M | 1.13B | 1.35B | 1.46B | 1.67B | |||||
Income Tax Expense | 72M | 163M | 260M | 101M | 301M | |||||
Earnings From Continuing Operations | 308M | 971M | 1.09B | 1.36B | 1.37B | |||||
Net Income to Company | 308M | 971M | 1.09B | 1.36B | 1.37B | |||||
Minority Interest | -29M | -5M | - | - | - | |||||
Net Income - (IS) | 279M | 966M | 1.09B | 1.36B | 1.37B | |||||
Net Income to Common Incl Extra Items | 279M | 966M | 1.09B | 1.36B | 1.37B | |||||
Net Income to Common Excl. Extra Items | 279M | 966M | 1.09B | 1.36B | 1.37B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 1.46 | 5.05 | 5.82 | 7.39 | 7.57 | |||||
Basic EPS - Continuing Operations | 1.46 | 5.05 | 5.82 | 7.39 | 7.57 | |||||
Basic Weighted Average Shares Outstanding | 191M | 191M | 188M | 184M | 181M | |||||
Net EPS - Diluted | 1.43 | 4.95 | 5.72 | 7.29 | 7.49 | |||||
Diluted EPS - Continuing Operations | 1.43 | 4.95 | 5.72 | 7.29 | 7.49 | |||||
Diluted Weighted Average Shares Outstanding | 195M | 195M | 191M | 186M | 183M | |||||
Normalized Basic EPS | 1.16 | 3.63 | 4.63 | 5 | 5.68 | |||||
Normalized Diluted EPS | 1.14 | 3.57 | 4.56 | 4.93 | 5.62 | |||||
Supplemental Items | ||||||||||
EBITDA | 1.83B | 2.5B | 2.57B | 2.72B | 2.92B | |||||
EBITA | 1.7B | 2.35B | 2.41B | 2.57B | 2.77B | |||||
EBIT | 810M | 1.45B | 1.86B | 2.07B | 2.28B | |||||
EBITDAR | 2.04B | 2.68B | 2.74B | 2.88B | 3.08B | |||||
Total Revenues (As Reported) | - | - | - | - | - | |||||
Effective Tax Rate - (Ratio) | 18.95 | 14.37 | 19.24 | 6.92 | 17.98 | |||||
Current Domestic Taxes | - | 16M | 24M | 21M | 44M | |||||
Current Foreign Taxes | 244M | 293M | 358M | 349M | 386M | |||||
Total Current Taxes | 244M | 309M | 382M | 370M | 430M | |||||
Deferred Domestic Taxes | -161M | -106M | -94M | -236M | -116M | |||||
Deferred Foreign Taxes | -11M | -40M | -28M | -33M | -13M | |||||
Total Deferred Taxes | -172M | -146M | -122M | -269M | -129M | |||||
Normalized Net Income | 222M | 696M | 869M | 919M | 1.03B | |||||
Non-Cash Pension Expense | -27M | -33M | -33M | -10M | -10M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | - | - | - | - | - | |||||
Selling and Marketing Expenses | - | - | - | - | - | |||||
Research And Development Expense From Footnotes | - | - | - | - | - | |||||
Net Rental Expense, Total | 209M | 184M | 171M | 160M | 158M | |||||
Imputed Operating Lease Interest Expense | 54.96M | 42.88M | 44.09M | 63.03M | 59.57M | |||||
Imputed Operating Lease Depreciation | 154M | 141M | 127M | 96.97M | 98.43M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 95M | 170M | 194M | 217M | 206M | |||||
Total Stock-Based Compensation | 95M | 170M | 194M | 217M | 206M |
- Stock Market
- Equities
- IQV Stock
- Financials Iqvia Holdings Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition